Tirofiban (glycoprotein Iib/iiia Inhibitor) in Patients with St- Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
نویسندگان
چکیده
Primary percutaneous coronary intervention (PCI) is the preferred method for early restoration of blood flow in the infarct-related vessel in patients with ST-segment elevation myocardial infarction (STEMI), and adjunctive anti-platelet therapy is found to be associated with clinical outcomes following primary PCI. Glycoprotein IIb/IIIa inhibitors(GPI) act by inhibiting the final common pathway of platelet aggregation, and play an important role in the management of acute STEMI. Tirofiban is a small molecule, non-peptide tyrosine derivative which belongs to the class of glycoprotein IIb/IIIa inhibitors.
منابع مشابه
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
BACKGROUND Current guidelines recommend abciximab as the preferred agent for patients undergoing primary percutaneous coronary intervention, yet small-molecule glycoprotein IIb/IIIa inhibitors are more commonly used in clinical practice. The objective of our meta-analysis was to evaluate for differences in clinical outcome between small-molecule glycoprotein IIb/IIIa inhibitors and abciximab in...
متن کاملPlatelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
BACKGROUND Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac complications in patients with acute coronary syndromes without ST-segment elevation and protect against thrombotic complications associated with percutaneous coronary interventions (PCIs). The question arises as to whether these 2 beneficial effects are independent and additive. METHODS AND RESULTS We an...
متن کاملAcute Serious Thrombocytopenia Associated with Intracoronary Tirofiban Use for Primary Angioplasty
Tirofiban, a specific glycoprotein IIb/IIIa inhibitor, may cause extensive thrombocytopenia with an incidence of 0.2% to 0.5%. We report the case of a 50-year-old man who developed thrombocytopenia after tirofiban use (both intracoronary and peripheral) over hours and the successful management of this complication after primary percutaneous coronary intervention for acute ST-segment elevation m...
متن کاملAppropriate Use of Glycoprotein IIb/IIIa Blockade for Unstable Angina and Non–ST Segment Elevation Myocardial Infarction
• Objective: To review the clinical trials of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors for unstable angina or non–ST segment elevation myocardial infarction (MI) and to provide a practice guide for the use of these agents in this setting. • Methods: Clinical trials relating to GPIIb/IIIa antagonists and acute coronary syndromes were identified from a MEDLINE search of articles published be...
متن کاملRationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high risk patients with non-ST elevation acute coronary syndrome referred for percutaneous coronary intervention) project: A multi-center, randomized, controlled clinic trial in Chinese patients
As a member of Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, Tirofiban had been shown to improve myocardial reperfusion and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), but the optimal timing of administration of Tirofiban remains unclear. In order to compare the effects of upstream versus downstream administration of Tirofiban in Chinese patients with mi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016